Lysosome Febs Advanced Course

08/04/2022

We’re delighted to invite you to the FEBS Advanced Course, ”360-degree Lysosome; from structure to genomics, from function to disease-update”, which will be held in Kusadası between 4-9 October, 2022!

08/04/2022

11/07/2021

Dr. Sema Kalkan Uçar is going to give a remarkable panel lecture: “: Clinical aspects of lysosomal storage diseases” in FEBS Advanced Lecture Course: 360° Lysosome on October 8, 2021 at 9.30 am!
Prof.Dr. Sema Kalkan Uçar received her M.D. from the Ege University, completed a residency in pediatrics at the Behcet Uz Hospital for Sick Children and a clinical fellowship in pediatric metabolic disease under the supervision of Prof. Dr. Mahmut Çoker at the Ege University, Izmir. Since 2011 Dr. Kalkan Uçar has been associate professor and since March 2017 she has been received a professor post in pediatrics at the Ege University. In 2003 Dr. Kalkan Uçar was awarded the long-term European Society for Paediatric Endocrinology Clinical Fellowship; in 2008 the Best Poster Prize from Lysosomal Storage Disorders Symposium, Paris; in 2014 Aliye Üster Foundation Research Award, in 2017 Nutricia metabolics research fund grant. She has participated in clinical trials, phase studies and published many articles focused on inherited metabolic diseases. Dr. Kalkan Uçar has a particular clinical interest in glycogen and lysosomal storage disorders, mitochondrial diseases, dyslipidemia and nutrition (ketogenic diet). She is a board member of Turkish National Association of Nutrition and Metabolism, member of Turkish Expert Board in Medicine and Society for The Study of Inborn Errors of Metabolism.
*Ds

04/07/2021

Dr. Volkan Seyrantepe is going to give a remarkable lecture: “Disturbed catabolic pathways in animal models of L*Ds” in FEBS Advanced Lecture Course: 360° Lysosome on October 9, 2021 at 14.30 pm!

Prof Seyrantepe’s research includes biological role of sialidases in complex cellular events such as glycolipid degradation and lysosomal storage diseases. As PI, Faculty, Senior Scientist and co-Investigator on national and international-funded grants (TUBITAK, EMBO, Marie Curie, German BMBF), Prof Seyrantepe has the expertise, leadership, training, and strong motivation necessary to carry out research projects in the field of lysosomal storage diseases. Dr. Seyrantepe successfully administered the projects collaborated with other researchers from USA, Canada, Japan, Germany, Denmark, Colombia and France, and produced several peer-reviewed publications. His current research mainly focuses on the better understanding of pathophysiology of lysosomal storage disease, Tay-Sachs using recently generated and validated mouse model. Dr Seyrantepe’s lab is also funded by TUBITAK through 3 COST ACTIONS: CA17103 DARTER (Delivery of Antisense RNA Therapies), CA18103 INOGLY (Innovation with Glycans: New Frontiers from Synthesis to New Biological Targets and CA19105 EpiLipidnet (Pan-European Network in Lipidomics and Epilipidomics) and Bosphorus Bilateral agreement fund between Turkey and France to further understand the etiopathogenesis of Tay-Sachs disease. Currently, his team uses siRNA based therapeutic approach to cure Tay-Sachs mouse model. He also investigates the combined effects of small drug molecules (rapamycine and lithium) on induction of autophagy in neurons, neuroglia and skin fibroblasts from Tay-Sachs Hexa-/-Neu3-/- mice as well as Tay-Sachs patients and address the role of N-glycans in the regulation of autophagy. His ongoing research may have potential to contribute for the development of new therapeutic strategies to cure devasting Tay-Sachs disease.

Honor: 2007 Foundation for research into Children’s diseases, Canada- Fondation de la recherche sur les maladies infantile”- Prix d’excellence 2007: Prix chercheur post-doctoral 2007 Best Post-Doctoral Researcher in Canada presented by Pfizer.

*Ds

01/07/2021

Dr. Karin Öllinger is going to give an outstanding lecture: “Restoration of lysosomal function after damage is accompanied by recycling of lysosomal membrane proteins” in FEBS Advanced Lecture Course: 360° Lysosome on October 7, 2021 at 10.30 am!
Karin Öllinger is professor and group leader at Department of Biomedical and at Linköping University in Sweden. Her current research focuses on lysosome dependent signaling including cell death through lysosomal membrane permeabilization, impact of lysosomal exocytosis and lysosomal repair mechanisms.
Karin Öllinger received her MSc in Chemistry and Biology from Linköping University in 1986 and PhD degree in 1992 from the same university. In 1999 she was certified as associate professor in Experimental Pathology and in 2004 promoted as Professor. Her current position is as Head of Division of Cell Biology at Linköping University.
She has published more than 80 peer-reviewed research articles, several reviews and the h-index in Web of Science is 33. She has also edited a volume on Lysosomes in the Springer series Methods in Molecular Biology.
*Ds

25/06/2021

Dr. Andrea Ballabio is going to give an amazing lecture: “Lysosomes as dynamic regulators of cell and organismal homeostasis” in FEBS Advanced Lecture Course: 360° Lysosome on October 7, 2021 at 9.30 am!
Dr. Andrea Ballabio obtained his M.D. degree at the University of Naples, Italy, where he completed his residency in Pediatrics. After working as post-doctoral fellow at the Institute of Genetics and Biophysics in Naples and at Guy’s hospital in London UK, in 1989 he moved to the Department of Molecular and Human Genetics of Baylor College of Medicine in Houston TX USA, where he became Associate Professor and Co-director of the Human Genome Center. At the end of 1994 he moved back to Italy to become the founder and director of the Telethon Institute of Genetics and Medicine (TIGEM). He is Professor of Medical Genetics at the Faculty of Medicine of the University of Naples “Federico II” and Visiting Professor at both Baylor College of Medicine in Houston, Texas. He was two-time winner of the Advanced European Research Council (ERC) 5 year-grant, in 2010 and in 2016. He was the winner of the 2106 Louis-Jeantet prize for Medicine. He is a Co-Founder of CASMA Therapeutics, a company focused on autophagy and based in Boston, MA. He has authored over 350 publications in international peer-reviewed journals.
The focus of Andrea Ballabio's research career has been on the elucidation of the mechanisms underlying genetic diseases. The contributions of his laboratory have spanned a wide range of biological processes and human diseases, from X chromosome-inactivation (the discovery of Xist), axonal targeting (Kallmann syndrome), melanosome biogenesis (Ocular albinism), mitochondrial biogenesis (Hereditary spastic paraplegia), embryonic development (Chondroplasia punctata and Opitz GBBB syndrome) and post-translational protein modification (Multiple sulfatase deficiency) to name a few. In the past few years he has focused his research on the lysosome and on the role of lysosomal dysfunction in lysosomal storage diseases (L*D) and common neurodegenerative diseases. His group discovered that in L*Ds lysosomal dysfunction leads to a block of the autophagic pathway with consequent accumulation of autophagy substrates, which contributes to the development of neurodegeneration in these diseases. More recently, his group discovered that lysosomal function and autophagy are subject to a global transcriptional regulation, which is mediated by the master gene TFEB.

*Ds

20/06/2021

Happy Father's Day!

18/06/2021

Dr. Andrés D. Klein is going to give an outstanding lecture: “Lysosome-associated Neurodegenerative disorders (Parkinson, Alzheimer, Down)” in FEBS Advanced Lecture Course: 360° Lysosome on October 8, 2021 at 10.30 am!

Andrés D. Klein received his B.Sc in Biochemistry and his Ph.D. in Cellular and Molecular Biology at the Pontificia Universidad Católica de Chile. Dr. Klein did a postdoc at Stanford University (2009-2011) and a second postdoc (2011-2015) at the Weizmann Institute of Science. Currently, he directs the Center for Genetics and Genomics at the Universidad del Desarrollo in Chile. Prof. Klein was awarded the young Chilean innovator prize by MIT technology reviews (2013), he was selected as one of the top 100 young Chilean leaders (2013), the Pew Innovation Fund (2018), among other recognitions.

Prof. Andrés D. Klein’s research interests include uncovering the genetic and cellular basis of phenotypic variability as a way for identifying novel therapeutic targets for rare and common genetic diseases. To this end he uses population based approached in yeast, flies, mice and humans. His work has led to the discovery of potential treatments for two genetic diseases (Niemann-Pick C and neuropathic Gaucher disease), using FDA-approved drugs.
*Ds

17/06/2021

Have you ever seen the venue of the course?
- Pine Bay Holiday Resort Hotel offers an ideal venue for any kind of meeting, incentives, conferences and events and is unparallelled in its use of technologically advanced facilities and equipment. Pine Bay has a conference hall with a capacity of 1200 people which can be divided into smaller halls.

- There are also 4 committee rooms for smaller and specialized meeting needs with connectivity for laptops. Cutting-edge technical support is readily available, together with a dedicated banquet team. Multi-purpose exhibition hall is also available which will be used for poster presentations of the workshop.

- The hotel has met the requirements of the "Assessment Criteria for COVID-19 and Hygiene Measures to be Implemented in the Hotels and their Food & BeverageVenues during the Pandemic" published within the framework of the "SafeTourism Certification Program" and has become entitled to receive "Safe Tourism Certificate".

- The hotel is responsible and caring means being consistent with their already high standards around hygiene, sanitization, and cleaning. Now more than ever, their priority is the health and safety of the guests and employees.

- They have listed some of the extra steps they took to ensure the guests and employees health and safety. The hotel have adopted a new standard of hotel cleanliness and disinfection. They built upon the already high standards of housekeeping and hygiene, where hospital-grade cleaning products and upgraded protocols are currently in use. They are frequent sanitizing high touch surfaces and high traffic areas, such as the reception, the lobby, restaurants, public bathrooms, and meeting rooms. For the guest rooms, they are using extra disinfection to top 10 high touch areas, such as lighting switches and door handles, as well as reduce paper amenities. They have placed hand sanitizers at entrances and high traffic areas. They have enhanced cleaning for the fitness center and spa.

- For dining venues, they have enhanced cleaning and made changes to buffets, in-room dining and meeting spaces. With evaluation of new technologies like electrostatic sprayers with disinfecting mist and ultraviolet light, they sanitize surfaces and objects regularly. Their team members safety and well-being has been ensured with personal protective equipment and enhanced training and protocols. They are ventilating entrances and high traffic public spaces regularly.

13/06/2021

Dr. Janko Kos is going to give a remarkable lecture: “Lysosomal peptidases in innate immune cells: implications for cancer immunity.” in FEBS Advanced Lecture Course: 360° Lysosome on October 9, 2021 at 14.30 pm!
Janko Kos received Ph. D. in biochemistry at the University of Ljubljana, Slovenia in 1991. He was a postdoctoral fellow or visiting professor at the Jozef Stefan Institute in Ljubljana, Max Planck Institute for Biochemistry, Martinsried, University of Sheffield, and University of Copenhagen. From 1995 to 2004 he was a Head of Department of Biochemical Research and Drug Design in Krka, Pharmaceutical Company. In 2006 he became a full professor of biochemistry at the University of Ljubljana, Faculty of Pharmacy. From 2007 to 2020 he was a Head of the Department of Biotechnology at Jozef Stefan Institute.
Janko Kos is involved in basic and translational studies of proteolytic enzymes and their inhibitors. He has been studying their role in cancer, immune and neurodegenerative diseases. His translational research was focused on the development of new diagnostics for application in oncology and in screening, design and evaluation of various types of protease inhibitors to be used in therapy. He published more than 270 scientific papers and book chapters and was frequently cited (h index 50). He is a President of Slovenian Biochemical Society, vice president of FEBS and a member of international boards and societies. He achieved several national an international honors and awards, from 2015 he is a member of European Academy of Sciences and Arts.

10/06/2021

The organizing team on work!

05/06/2021

Dr. Marie T. Vanier is going to give an important lecture in Laboratory Diagnosis And Screening Panel: “ Diagnostic tests of L*Ds: past, present, future in FEBS Advanced Lecture Course: 360° Lysosome on October 8, 2021 at 13.30 pm!
Marie T. Vanier, MD, PhD, received her university degrees and medical training in Lyon, France, and Göteborg, Sweden. She was a Director of Research (grade equivalent to Full Professor), now honorary, at the French Institute of Health and Medical Research (INSERM). Alongside this position, she was for over 30 years the Head of a laboratory offering diagnostic services for lysosomal (biochemistry and molecular genetics) and peroxisomal (biochemistry) diseases at Lyon University Hospitals. Among lysosomal diseases, neurolipidoses constitute her main focus of interest. She has authored over 200 articles in peer-reviewed journals and a number of book chapters. Her early work focused on Krabbe disease, her later main line of research has been on Niemann-Pick diseases, more particularly Niemann-Pick type C (NPC). Her contribution to NPC covers natural history of disease, description of less common clinical forms, delineation of a second genetic complementation group, development of diagnostic tests, genotype/phenotype correlations, pathophysiological aspects, as well as participation in preclinical therapeutic studies. She is also working with several patients organizations, in France and internationally.

03/06/2021

The deadline for abstract submission and registration have been delayed to 30th July, 2021! Don't miss the chance to share your work! More information about the submission and the bursaries go to: https://lysosome2021.febsevents.org/

01/06/2021

Yoshinori Ohsumi, The Nobel Prize in Physiology or Medicine 2016
Prize motivation: "for his discoveries of mechanisms for autophagy."
For many years, scientists could only study autophagy by examining cells with electron microscopes. Using this tool, they established that after autophagosomes form, they fuse to the lysosomal membrane to form a structure known as the autolysosome. Then, depending on the stimuli that initiated the autophagy process, the cargo is either degraded or recycled.
In 1992, Yoshinori Ohsumi and his colleagues at the University of Tokyo discovered that autophagy also occurs in yeast. Using a light microscope, they noticed that a few hours after starving yeasts of nutrients, the vacuole (which functions like our lysosomes) was filled with vesicles containing chunks of cytoplasm. These vesicles originate in the cytoplasm and then fuse with the lysosome, exactly as in animal and plant cells. Being able to use yeasts as an experimental model opened the door for studying the molecular biology of the autophagic machinery (and for identifying the key proteins that participate in the process) (Takeshige et al. 1992). / NATURE
“All I can say is, it’s such an honor,” Dr. Ohsumi told reporters at the Tokyo Institute of Technology after learning he had been awarded the Nobel, according to the Japanese broadcaster NHK. “I’d like to tell young people that not all can be successful in science, but it’s important to rise to the challenge.” / The New York Times

29/05/2021

Dr. Sergio Grinstein is going to give a distinguished lecture: “Molecular mechanisms of phagosome-endoplasmic reticulum contacts: Kissing and not running” in FEBS Advanced Lecture Course: 360° Lysosome on October 6, 2021 at 2 pm!

Dr. Sergio Grinstein completed his Ph.D. in 1976 at the Centro de Investigacion y Estudios Avanzados, in Mexico City. He then spent two years as a post-doctoral fellow at the Hospital for Sick Children in Toronto, followed by a year in the Department of Biochemistry at the Federal Institute of Technology in Zurich. He is currently working at the Hospital for Sick Children in Toronto and has been Professor of Biochemistry at the University of Toronto since 1988.
Dr. Grinstein is interested in two areas: the cell physiology and biophysics of innate immunity –particularly phagocytosis and host-pathogen interactions– and the regulation of the intracellular pH.

26/05/2021

Don't miss this rare opportunity to listen to our keynote speakers during the FEBS Advanced Lecture Course: 360° Lysosome on October 5, 2021!


For details: https://lysosome2021.febsevents.org/

22/05/2021

Dr. Devrim Gozuacik is going to give a remarkable lecture: “Autophagy regulation in health and disease” in FEBS Advanced Lecture Course: 360° Lysosome on October 6, 2021 at 11.30 am!

Professor Devrim Gozuacik obtained his MD degree from Hacettepe School of Medicine. He received his MS degree of Biochemistry from Ecole Polytechnique and Paris-Sud University and his PhD degree of cancer cell biology from Pasteur Institute and Necker Children's Hospital Research Center in Paris. Then, he moved to the Weizmann Institute of Science for his postdoctoral studies on cancer-cell death connections. After a 14 years of academic career in Sabanci University, he was appointed as a Research Professor in Koç University School Of Medicine and in Koç University Research Center for Translational Medicine (KUTTAM). Prof. Gozuacik also serves as Board Member of the International Cell Death Society, as the Associate Editor of the Autophagy journal, and as an Affiliate Member and an Advisory Board Member of the NIH-supported AIM Center of Biomedical Research Excellence in the University of New Mexico, USA. He is the author of >100 publications that received around 10.000 citations, and a recipient of several scientific awards, including EMBO-SDIG Award, TGC Sedat Simavi Award, TÜBA-GEBİP Award, IKU Onder Oztunali Award and Elginkan Technology Award.


Dr Gozuacik's research focuses on the study of basic autophagy signaling in mammalian cells and autophagy abnormalities in diseases, including cancer, neurodegeneration and rare diseases.

09/05/2021

Happy Mother's Day!